ANI Snaps Up Novitium In Deal Worth Up To $210m
Pipeline Includes 505(b)(2) Products; Transaction Also Bolsters CDMO Business
Executive Summary
ANI Pharmaceuticals has struck a deal worth up to $210m to acquire niche generics specialist Novitium Pharma, a move that the firm says will bring it a healthy pipeline of ANDAs and 505(b)(2) products as well as enhancing its CDMO business.
You may also be interested in...
FTC Gives Green Light To ANI-Novitium Acquisition Conditions
ANI is now firmly in the clear for its $210m acquisition of Novitium, following FTC approval of an order requiring divestiture of rights and assets to two generic products. The US-based firm is on an upward trajectory following its recent approval for Cortrophin Gel.
ANI Pharmaceuticals Completes $210m Novitium Acquisition
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
ANI Ready For Full-Scale Commercial Launch Of FDA-Approved Cortrophin Gel
ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.